Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Vanda Pharmaceuticals Inc.    VNDA

VANDA PHARMACEUTICALS INC. (VNDA)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Vanda Pharmaceuticals : Receives Negative Opinion for Marketing Authorization from the European Medicines Agency on Fanaptum(TM) for the Treatment of Schizophrenia

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/10/2017 | 10:06pm CEST

WASHINGTON, Nov. 10, 2017 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) announced today the refusal of the marketing authorization application (MAA) of Fanaptum(TM) (oral iloperidone tablets) for the treatment of schizophrenia in adult patients in the European Union. In July 2017, the Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion, recommending the refusal of the Fanaptum(TM) MAA. Vanda requested a re-examination of the initial opinion. After considering the grounds for this request, the CHMP re-examined the opinion and confirmed the refusal of the Fanaptum(TM) MAA on November 9, 2017.

About Vanda Pharmaceuticals Inc.
Vanda is a global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com.

About Fanapt(®)

For full U.S. Prescribing Information for Fanapt(®), including indication, Boxed Warnings and Important Safety Information, visit our Web site at www.fanapt.com.

Investor Contact:
Jim Kelly
Executive Vice President & Chief Financial Officer
Vanda Pharmaceuticals Inc.
(202) 734-3428
[email protected]

View original content:http://www.prnewswire.com/news-releases/vanda-receives-negative-opinion-for-marketing-authorization-from-the-european-medicines-agency-on-fanaptum-for-the-treatment-of-schizophrenia-300554039.html

SOURCE Vanda Pharmaceuticals Inc.


© PRNewswire 2017
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on VANDA PHARMACEUTICALS INC.
07/20VANDA PHARMACEUTICALS : to Announce Second Quarter 2018 Financial Results on Aug..
AQ
07/17VANDA PHARMACEUTICALS : to Announce Second Quarter 2018 Financial Results on Aug..
PR
07/10Complimentary Technical Snapshots on Trevena and Three More Biotech Stocks
AC
06/14VANDA PHARMACEUTICALS : Patent Issued for Method and Composition for Treating a ..
AQ
06/13VANDA PHARMACEUTICALS INC. : Submission of Matters to a Vote of Security Holders..
AQ
06/05VANDA PHARMACEUTICALS : Announces Participation at June 2018 Investor Conference..
AQ
06/01VANDA PHARMACEUTICALS INC. : Entry into a Material Definitive Agreement, Termina..
AQ
06/01VANDA PHARMACEUTICALS : Announces Participation at June 2018 Investor Conference..
PR
05/23VANDA PHARMACEUTICALS INC. : Other Events, Financial Statements and Exhibits (fo..
AQ
05/17VANDA PHARMACEUTICALS : to Present at the Deutsche Bank 43rd Annual Health Care ..
AQ
More news
News from SeekingAlpha
07/17Playing The Expectations Game In Biotech 
06/19INSTITUTIONAL TOP IDEAS : Great Point Partners 
05/23Vanda's Hetlioz effective in jet lag study 
05/23Premarket analyst action - healthcare 
05/10Vanda Pharmaceuticals (VNDA) Presents At 43rd annual Deutsche Bank Healthcare..